In recent years, molecular profiling has identified numerous oncogenic driver mutations (i.e., EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase; KRAS, Kirsten Rat Sarcoma Viral Oncogene; ROS1, c-ros Oncogene 1; BRAF, B-Raf Proto-Oncogene; MET, MET Pro-to-Oncogene; RET, Ret Pro-to-Oncogene; NTRK, Neurotrophic Tyrosine Receptor Kinase) which occur in roughly 40–50% of NSCLC cases [2]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.